BIOSYENT INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.64 CAD | -0.12% |
|
-0.12% | -6.29% |
| Apr. 01 | BioSyent To Present At LD Micro New York Investor Conference | MT |
| Mar. 13 | Tranche Update on BioSyent Inc. (TSXV:RX)'s Equity Buyback Plan announced on December 13, 2022. | CI |
| Sales 2024 * | 35M 25.39M | Sales 2025 * | 38.7M 28.07M | Capitalization | 100M 72.89M |
|---|---|---|---|---|---|
| Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 2.87 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.6 x |
| P/E ratio 2024 * |
18.4
x | P/E ratio 2025 * |
15.4
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.46% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioSyent Inc.
More press releases
More news
| 1 day | -0.12% | ||
| 1 week | -0.12% | ||
| Current month | -0.69% | ||
| 1 month | +1.53% | ||
| 3 months | -0.12% | ||
| 6 months | +8.00% | ||
| Current year | -6.29% |
1 week
8.55
8.65
1 month
8.418.75
Current year
8.409.02
1 year
7.039.26
3 years
6.2410.00
5 years
3.1310.00
10 years
3.1312.82
| Managers | Title | Age | Since |
|---|---|---|---|
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Robert March
DFI | Director of Finance/CFO | - | 18-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 14-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 18-01-07 |
René C. Goehrum
CEO | Chief Executive Officer | 64 | 95-12-31 |
Peter Lockhard
BRD | Director/Board Member | 60 | 02-05-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 8.64 | -0.12% | 1,400 |
| 24-04-12 | 8.65 | +0.58% | 2,200 |
| 24-04-11 | 8.6 | +0.23% | 3,260 |
| 24-04-10 | 8.58 | -0.23% | 5,900 |
| 24-04-09 | 8.6 | -0.58% | 42,453 |
Delayed Quote Toronto S.E., April 15, 2024 at 03:59 pm EDT
More quotes
BioSyent Inc. is a specialty pharmaceutical company. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary operates the Companyâs business marketing biologically and health friendly non-chemical insecticides. Its products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Cathejell combines sterile gel and 2% lidocaine jelly in a collapsible syringe that is ready to use. FeraMAX Pd Therapeutic 150 is an oral hematinic that helps the body form red blood cells and is indicated for the treatment of iron deficiency anemia.
Sector
Pharmaceuticals
Calendar
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
8.65
CAD
Average target price
9
CAD
Spread / Average Target
+4.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.29% | 73.03M | |
| +28.79% | 677B | |
| +25.94% | 560B | |
| -5.84% | 355B | |
| +15.75% | 319B | |
| +4.32% | 287B | |
| +4.00% | 214B | |
| +1.92% | 207B | |
| -7.93% | 199B | |
| -10.00% | 146B |
- Stock Market
- Equities
- RX Stock
